Sun W, Gao C, Hartana C, Osborn M, Einkauf K, Lian X, et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature. 2023;614:309-317 pubmed publisher

Gerace D, Zhou Q, Kenty J, Veres A, Sintov E, Wang X, et al. Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Rep Med. 2023;4:100879 pubmed publisher

Reda M, Ngamcherdtrakul W, Nelson M, Siriwon N, Wang R, Zaidan H, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13:4261 pubmed publisher

Staudte S, Klinghammer K, Jurmeister P, Jank P, Blohmer J, Liebs S, et al. Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers. Cancers (Basel). 2022;14: pubmed publisher

Liu C, Liu W, Ma H, Chen Y, Hueng D, Tsai W, et al. Interstitial Control-Released Polymer Carrying a Targeting Small-Molecule Drug Reduces PD-L1 and MGMT Expression in Recurrent High-Grade Gliomas with TMZ Resistance. Cancers (Basel). 2022;14: pubmed publisher

Winkler C, King M, Berthe J, Ferraioli D, Garuti A, Grillo F, et al. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. JCI Insight. 2021;6: pubmed publisher

Liu Z, Ning F, Cai Y, Sheng H, Zheng R, Yin X, et al. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells. Cancer Commun (Lond). 2021;41:62-78 pubmed publisher

Bhattacharya S, Calar K, Evans C, Petrasko M, de la Puente P. Bioengineering the Oxygen-Deprived Tumor Microenvironment Within a Three-Dimensional Platform for Studying Tumor-Immune Interactions. Front Bioeng Biotechnol. 2020;8:1040 pubmed publisher

Wang H, Fu C, Du J, Wang H, He R, Yin X, et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res. 2020;39:29 pubmed publisher

Kim J, Ghosh A, Ayithan N, Romani S, Khanam A, Park J, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep. 2020;10:1835 pubmed publisher